Acute Myeloid Leukemia Coverage From Every Angle

Recent News

Absolute Monocyte and Lymphocyte Counts in AML: Prognostic Significance at the Time of Relapse
Is the Presence of RUNX1 Mutations an Adverse Risk Factor in AML?
Anti-CD117 Monoclonal Antibody Plus Nonmyeloablative Conditioning in Older Patients With AML
FDA Brief: SNDX-5613 Receives Fast Track Designation for Certain Resistant Acute Leukemias
ASCO 2021: Exploring the Molecular Architecture of Extramedullary AML
EHA2021: Correlating MRD and Outcomes With Venetoclax and Azacitidine in AML
ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML
EHA2021: Venetoclax Plus Gilteritinib Under Study in Resistant FLT3-Mutated AML
ASCO 2021: Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy
EHA2021: Post Hoc Analysis of Oral Azacitidine in AML From QUAZAR AML-001 Trial
ASCO 2021: Novel FLT3 Inhibitor Under Study in Resistant AML
ASCO 2021: Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML
Australian Researchers Use Novel Work Utility Measure to Assess Productivity Impact of AML
Trousseau Syndrome and AML: Case Report
Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts
Quizartinib Combinations Under Study in FLT3-ITD–Mutated AML
Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers
Pilot Study in AML: Can Biomarkers Predict Chemotherapy-Related Infection?
Dactinomycin Under Study in Management of Resistant NPM1-Mutated AML
Have Outcomes in AML Improved Over the Past 40 Years?
CPX-351 for High-Risk AML: Phase III Post Hoc Analysis
AACR 2021: Daratumumab Plus Venetoclax Under Study in AML
Chemotherapy Intensity, MRD Status, and Outcomes in AML
AACR 2021: Is SIRT5 Enzyme Potential Therapeutic Target in AML?
Optimal Number of Chemotherapy Courses for Younger Patients With AML
Testing for Germline Mutations in Elderly Patients With AML
Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML
Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML
Predicting Response to Venetoclax Combination Therapy in Resistant AML
Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML
Case Report: Central Diabetes Insipidus and AML
Using Existing Drugs to Treat Unique Subtype of NPM1-Mutated AML
Phase II French Trial of Eprenetapopt Plus Azacitidine in AML
Prognostic Impact of IDH Mutational Status in AML After HSCT
Can Fractionated Myeloablative Busulfan Regimen Improve Outcomes in Older Patients With AML?
Could AML Progression Be Fueled by Chemotherapy-Induced Dormancy of AML Cells?
Is MRD Status Predictive of Survival in Resistant AML?
Association Between Pretransplant Molecular MRD and Outcomes in AML
Novel Combination Results in Anticancer ‘Double Whammy’ in AML
TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML
TCT 2021: CPX-351 Versus Chemotherapy for High-Risk of Secondary AML
TCT 2021: Effects of HSCT After Azacitidine Therapy for AML
Does Exposure to Occupational Pesticides Increase the Risk for AML?
TCT 2021: JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML
Eprenetapopt Plus Azacitidine Under Study in TP53-Mutant AML
Decitabine Plus Venetoclax Versus Chemotherapy Among Older Patients With AML

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.